Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

• Adverse events led to dose reduction or discontinuation in patients treated with camizestrant.
• Treatment combinations included camizestrant with abemaciclib, palbociclib, or ribociclib, with various dosing options.
• Data presented as number and percentage of affected patients highlights the variability in treatment response.
• The findings emphasize the importance of monitoring adverse effects in advanced breast cancer treatments.